Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Nortran Pharmaceutical -NRT.V -- Ignore unavailable to you. Want to Upgrade?

To: Wisee who wrote (975)	10/28/1998 10:30:00 AM
From: chevalier	Read Replies (1) \| Respond to of 1185

More noticeable volume in the stock today. Technically this stock is forming a classic triangle formation that is getting ready to break ou it appears. Volume is the key to watch and so far today its traded 180,000 shares and its not even 10:30 am. Just picked up some shares at $1 and will sit with them until this thing breaks out. The stock has put in a nice bottom in this range IMO

To: Wisee who wrote (975)	11/19/1998 8:27:00 PM
From: Wisee	Read Replies (3) \| Respond to of 1185

Referring to my earlier post (#975), Nortran continues to deliver on their promises: 1. HR: hiring of new VP of Business Development. The hiring of Mr. Joseph Rus (formerly of Hoffman LaRoche) in Oct. /98 is excellent news for Nortran. I think, if anybody knows how the Hoffman LaRoche studies are going on Nortran's compounds, he is the person that would probably know. We are a little disappointed that Nortran has not formally announced this exciting new appointment. ______________________________________________________________________ 2. Local anaesthetic: Phase II trial completed - independent investigator preparing analysis of data for final report. No news yet, but we expect news by year-end. ______________________________________________________________________ 3. Licensing/collaborations: Nortran preparing for visit by another large pharmaceutical company. Wow, we thought this deal with a European pharmaceutical co. would take at least 6 months to complete, and here it is, a deal with Astra is done within a month. Now Nortran has partnership agreements with two of the world's major pharmaceutical companies. We are amazed that Nortran's market cap. still remains around $30 million. Sooner or later the market will realize Nortran's potential, but by that time the stock will be $3 to $5. ______________________________________________________________________ 4. Hoffmann La Roche: Nortran synthesizing 25g quantities of two AFA compounds for Roche. The results to date have gone exceptionally well! The fact that Mr. Rus quit Hoffman LaRoche to join Nortran re-confirms this fact. Should be exciting times for Nortran in 1999. Wisee